Obinutuzumab in combination with mycophenolate mofetil is in clinical development for the
treatment of class III or class IV lupus nephritis (LN) in adults. LN is a manifestation of a disease
called systemic lupus erythematosus (SLE). In LN, the immune system (the body’s natural
defences) attacks the kidneys, causing inflammation and kidney damage. LN remains a substantial
cause of morbidity and mortality in lupus patients. Treatment of LN has been challenged by the
limited number of effective medicinal products and side-effects associated with them.
Obinutuzumab with mycophenolate mofetil for treating lupus nephritis
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Partners-Industry_Motifs_Motifs_Conduction-broadcasting_RGB-scaled_edited_1233.jpg)
Obinutuzumab in combination with mycophenolate mofetil is in clinical development for the treatment of class III or class IV lupus nephritis (LN) in adults. LN is a manifestation of a disease called systemic lupus erythematosus (SLE).
Interventions:
Mycophenolate mofetil (Cellcept)
, Obinutuzumab (Gazyvaro; RO5072759; GA101; Afutuzumab)
Indications:
Lupus nephritis
Year:
2023